At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 21 enrolled
Drug / intervention
Capecitabine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Dose Escalating (Phase I) Study Looking at the Biomodulation of Capecitabine by Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer
In Brief
A Phase 1 clinical trial evaluating Capecitabine, Docetaxel, and 1 other intervention for Pancreatic Cancer. Completed, enrolled 21 participants across 2 sites.
Detailed Summary
The primary purpose of this study is to define the maximum tolerated dose of combination docetaxel, gemcitabine, and capecitabine in patients with pancreatic cancer. Adverse effects will be measured in study participants. In addition, researchers will assess data about preliminary efficacy in patients with this treatment approach.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesUnited States
CollaboratorsUniversity of Michigan Rogel Cancer Center
Timeline
Phase 1CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2005
First PostedMay 2006
Primary CompletionOct 2008
Study CompletionJan 2011
TodayJul 2026
First PostedMay 3, 2006
Enrollment StartDec 1, 2005
Primary CompletionOct 1, 2008
Study CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 20.2 years ago
Interventions
Capecitabinedrug
Will be give on days 8-21
Docetaxeldrug
Will be given on days 1 and 8,
Gemcitabinedrug
A fixed dose rate will be give on days 8 and 15.